- Companies
- ByHeart
ByHeart Funding, Investors & Competitors
ByHeart has raised $255M across 3 funding rounds, most recently a $95M Series C in May 2024.
Last ByHeart funding round
$95M
Series C · May 2024
Cumulative funding ByHeart raised
$255M
across 3 funding rounds
Key investors in ByHeart
Polaris Partners
D1 Capital Partners
Red Sea Ventures
Two River
OCV
Bellco Capital
Gaingels
AF Ventures
About ByHeart
ByHeart is a New York-headquartered infant nutrition company founded in 2016 producing whole milk-based formulas mimicking breast milk composition. Its patented blends prioritize immune support, microbiome balance, cognitive development, and digestive health using organic ingredients like lactose, nonfat milk, and prebiotics in small-batch production. Available nationwide via subscription and retail, products undergo third-party testing for purity and meet FDA standards.
Founded
2016
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Subscription
ByHeart Funding History
ByHeart has raised a total of $255M across 3 funding rounds.
ByHeart's first fundraising round was a $70M Series A in April 2020. The most recent completed round was a $95M Series C in May 2024.
ByHeart funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| May 2024 | Series C | Bellco Capital; AF Ventures; Polaris Partners; Red Sea Ventures; Two River; OCV; D1 Capital Partners; Gaingels | $95M | ByHeart is a New York-based infant nutrition company founded in 2016, specializing in clinically validated, breast milk-inspired infant formulas that improve digestion, reduce spitting up, promote better weight gain, and enhance nutrient absorption. The company maintains end-to-end control over production through facilities in Pennsylvania, Oregon, and Iowa, enabling it to triple production capacity to serve about 15% of the U.S. market. Certified as a Clean Label Project brand, ByHeart emphasizes premium ingredients, advanced nutrition science, and a proprietary recipe, positioning itself in the stagnant infant formula industry with evidence-based innovation. On May 13, 2024, ByHeart announced $95 million in new financing from investors including D1 Capital Partners, Bellco Capital, Polaris Partners, Two River, OCV Partners, AF Ventures, Red Sea Ventures, and Gaingels, bringing total funding to $395 million. The round supports the ongoing U.S. commercial launch, expansion of the innovation pipeline, additional manufacturing investments, scientific advancement, and retail growth, including entry into Thrive Market and plans for more locations by end-2024. CEO Ron Belldegrun highlighted the commitment to transforming the industry, while Polaris Partners, the board chair, praised ByHeart's infant-first mission. ByHeart is rapidly expanding operations and retail presence, such as at Sam's Club, while advocating for industry improvements through initiatives like Operation Stork Speed. The company provides parent support via a 24/7 hotline and focuses on high-quality, accessible nutrition. Other sources mention a $500M valuation for a December 2024 Series C with different investors (TCG, SoftBank) and a later Series D in 2025. Sources indicate strong investor confidence in ByHeart's growth potential in the FoodTech and infant nutrition sectors, with over 250 employees and plans for market expansion. |
| Jul 2021 | Series B | D1 Capital Partners (lead); Bellco Capital; Hyperlink Ventures; AF Ventures; Polaris Partners; Red Sea Ventures; Two River; OCV; Gaingels | $90M | ByHeart is a baby nutrition company founded by Ron Belldegrun and Mia Funt, focused on developing advanced infant formula using certified organic, grass-fed whole milk and a patented protein blend designed to closely mimic breast milk. The company completed a $70M Series A round in April 2020 led by Polaris Partners, D1 Capital Partners, and OCV Partners, with participation from Red Sea Ventures, Sean Parker, Bellco Capital, and Two River affiliates, ahead of its first product launch in 2021. ByHeart conducted a multi-site, 311-baby clinical trial—the largest by a new US infant formula brand in over 25 years—which successfully met all endpoints. On July 26, 2021, ByHeart announced a $90M Series B funding round led by D1 Capital Partners, with continued investment from Series A backers OCV Partners, Polaris Partners, Bellco Capital, Two River, and Red Sea Ventures, plus new investors AF Ventures and Gaingels. The round coincided with the completion of its clinical trial, validating the product's efficacy. Investors expressed confidence in the team's differentiated formula, with D1's Dan Sundheim noting early investment due to its potential benefits for babies. ByHeart maintains control over manufacturing through facilities in Pennsylvania, Oregon, and Iowa, positioning it amid supply chain challenges in the infant formula industry. Later developments include a reported $95M Series C in December 2024 at $500M valuation led by TCG and SoftBank Vision Fund, and a $72M raise per a federal filing amid retail expansion into Walmart, Whole Foods, and Wegmans, reaching over 70% of US infant formula sales channels and becoming a top 10% product in under a year. |
| Apr 2020 | Series A | D1 Capital Partners (lead); OCV (lead); Polaris Partners (lead); Sean Parker; Bellco Capital; Red Sea Ventures; Two River | $70M | ByHeart, a baby nutrition company founded in 2016 by Mia Funt and Ron Belldegrun, closed a $70 million Series A funding round on April 15, 2020, led by Polaris Partners, D1 Capital Partners, and OCV Partners. Additional investors included Red Sea Ventures, Sean Parker, Bellco Capital, and affiliates of Two River. The funding was secured ahead of the company's first infant formula product launch planned for 2021. ByHeart focuses on developing innovative infant formulas and baby foods emphasizing next-to-nature quality, leading nutrition science, production transparency, and benefits for immune, cognitive, digestive, and microbiome health. The Series A round brought experienced board members including Amy Schulman from Polaris Partners, who previously led Pfizer Baby Nutrition, Hemi Zucker from OCV Partners, and Mike Tully as an observer from D1 Capital Partners. Existing investors like Arie Belldegrun from Bellco Capital and Joshua Kazam from Two River also joined the board. This Series A followed ByHeart's early development phase and preceded a $90 million Series B in July 2021, led by D1 Capital Partners with participation from the same Series A investors plus AF Ventures and Gaingels. The Series B supported the launch of ByHeart's first formula after completing a 311-baby clinical trial meeting all endpoints, targeting a $70 billion global mom and baby nutrition market. |
Who has invested in ByHeart?
10 investors have backed ByHeart across its funding rounds, including Polaris Partners, D1 Capital Partners, Red Sea Ventures, Two River, OCV and Bellco Capital.
Lead investors include D1 Capital Partners, OCV and Polaris Partners.
ByHeart Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Apr 2020 | ||
| 3 | Lead | Apr 2020 | ||
| 3 | Participant | Apr 2020 | ||
| 3 | Participant | Apr 2020 | ||
| 3 | Lead | Apr 2020 | ||
| 3 | Lead | Apr 2020 | ||
| 2 | Participant | Jul 2021 | ||
| 2 | Participant | Jul 2021 | ||
This data is available for Pro users. Sign up to see all 10 ByHeart investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by ByHeart
ByHeart has acquired 1 company to date.
Last acquisition by ByHeart was on January 5th 2023. ByHeart acquired Cascadia Nutrition for undisclosed valuation.
Latest Acquisitions by ByHeart
| Description | Cascadia Nutrition is a contract manufacturer specializing in nutritional supplements and formulas. Based in the United States, the company manages sourcing, logistics, production, exporting, and private labeling for dietary products. It offers on-demand single-unit production alongside larger runs, ensuring compliance with GMP standards. Services cater to brands in vitamins, proteins, and wellness supplements distributed globally. |
| HQ Country | |
| HQ City | Portland, OR |
| Deal Date | 5 Jan 2023 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all ByHeart acquisitions and their M&A valuation multiples. Start Free Trial | |
ByHeart Competitors
ByHeart competitors include listed companies like Coca-Cola, Nestlé, PepsiCo and AB InBev, and private ones like Bobbie and Chobani.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $165M | - | $570M | 3.5x | ||
| Publicly listed | $48B | $18B | $379B | 8.3x | ||
| Publicly listed | $109B | $19B | $245B | 2.8x | ||
| Publicly listed | $94B | $16B | $182B | 2.3x | ||
| Publicly listed | $59B | $20B | $157B | 3.6x | ||
| Private | $3.8B | - | $20B | 5.3x |
ByHeart Public Comps
ByHeart is still privately-owned, but its public comps include Coca-Cola, Nestlé, PepsiCo, AB InBev, Unilever, Monster Beverage, Mondelez, Nongfu Spring, Hindustan Unilever and Coca-Cola Europacific Partners.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $48B | $18B | 8.5x | 8.3x | 22.8x | 24.1x | |||
| $109B | $19B | 2.9x | 2.8x | 16.2x | 14.4x | |||
| $94B | $16B | 2.4x | 2.3x | 14.5x | 11.8x | |||
| $59B | $20B | 3.9x | 3.6x | 11.7x | 10.0x | |||
| $58B | $12B | 2.9x | 2.8x | 13.6x | 12.4x | |||
| $8.3B | $2.5B | 10.1x | 9.0x | 33.3x | 28.9x | |||
| $39B | $4.7B | 2.6x | 2.5x | 21.4x | 14.9x | |||
| $7.8B | $3.5B | 6.9x | 6.3x | 15.2x | 14.0x | |||
This data is available for Pro users. Sign up to see all ByHeart competitors and their valuation data. Start Free Trial | ||||||||
Common questions about ByHeart
| When was ByHeart founded? | ByHeart was founded in 2016. |
| Where is ByHeart headquartered? | ByHeart is headquartered in New York City, NY, United States. |
| Is ByHeart publicly listed? | No, ByHeart is a private, VC-backed company. |
| How much funding has ByHeart raised? | ByHeart has raised $255M across 3 funding rounds. |
| What was ByHeart's last funding round? | ByHeart's last funding round was a $95M Series C in May 2024. |
| Who are ByHeart's investors? | ByHeart's investors include Bellco Capital, Polaris Partners, Red Sea Ventures, Two River, OCV, D1 Capital Partners, AF Ventures, Gaingels, Sean Parker and Hyperlink Ventures. |
| Which companies are comparable to ByHeart? | Companies comparable to ByHeart include Bobbie, Coca-Cola, Nestlé, PepsiCo, AB InBev and Chobani. |
| How many companies has ByHeart acquired? | ByHeart has acquired 1 company, including Cascadia Nutrition. |
See companies similar to ByHeart
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




